Literature DB >> 21422425

Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.

Katsuhiro Masago1, Masako Miura, Yoshiro Toyama, Yosuke Togashi, Michiaki Mishima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21422425     DOI： 10.1200/JCO.2010.34.0216

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Approach to the patient with anaplastic thyroid carcinoma.

Authors:  Robert C Smallridge
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

2.  Epidermal growth factor mutation as a diagnostic and therapeutic target in metastatic poorly differentiated thyroid carcinoma: a case report and review of the literature.

Authors:  Hazel Lote; Jaishree Bhosle; Khin Thway; Kate Newbold; Mary O'Brien
Journal:  Case Rep Oncol       Date:  2014-06-18

3.  Prediction of drugs having opposite effects on disease genes in a directed network.

Authors:  Hasun Yu; Sungji Choo; Junseok Park; Jinmyung Jung; Yeeok Kang; Doheon Lee
Journal:  BMC Syst Biol       Date:  2016-01-11

4.  Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.

Authors:  Maurice de Wit; Ya Gao; Darlene Mercieca; Iris de Heer; Bart Valkenburg; Martin E van Royen; Joachim Aerts; Peter Sillevis Smitt; Pim French
Journal:  EBioMedicine       Date:  2020-06-05       Impact factor: 8.143
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.